A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

You may be eligible if

• Patients must be between 18 and 70 years old.
• All stages of patients with low-, intermediate- or high-grade non-Hodgkin's lymphomas, or Hodgkin's disease who have disease following standard chemotherapy.
• Stage II-IV patients with previously untreated low-grade lymphoma or untreated low-grade with progression.
• Patients must have received less than or equal to 2 prior combination chemotherapy regimens, no combination chemotherapy refractory disease, no high-dose chemotherapy with stem cell rescue, and may not have CNS involvement by lymphoma.
• Pathology slides must be reviewed and a diagnosis of lymphoma confirmed by the Hematopathology Section, Laboratory of Pathology, NCI.
• No patients with a history of coronary artery disease with angina pectoris and/or an ejection fraction less than 42 percent.
• Serum creatinine clearance greater than 50 cc/min, bilirubin less than 2.5 u and AST/ALT less than 2x normal, absolute neutrophil count greater than 1000/mm(3) and platelet count greater than or equal to 100,000/mm(3) unless due to respective organ involvement by tumor.
• Patients must have an ECOG performance status less than or equal to 2.
• Patients must be HIV negative.
• Pregnant women will be excluded.
• Patients must be able to give informed consent.
• Patients who, in the opinion of the principal investigator, are poor psychiatric or medical risks because of non-malignant systemic disease will be excluded.
• A completed eligibility form.